Mov Disord Vol 33, Suppl 2 Archives - Page 109 of 177 - MDS Abstracts

2018 International Congress
Neurophysiological correlates of bradykinesia in Parkinson’s disease
M. Bologna, A. Guerra, G. Paparella, L. Giordo, D. Alunni Fegatelli, AR. Vestri, J. Rothwell, A. Berardelli (Rome, Italy)
Objective: In the present study we aimed to investigate whether objective measures of bradykinesia in Parkinson’s disease have any relationship with neurophysiological measures in primary…
2018 International Congress
Properties of oscillatory neuronal activity in the basal ganglia and thalamus in patients with Parkinson’s disease
P. Zhuang, M. Hallett, G. Du, Y. Zhang, Y. Li (Beijing, China)
Objective: To characterize the firing rate and pattern of oscillatory neurons in basal ganglia and thalamus in patients with Parkinson’s disease (PD). Background: The cardinal…
2018 International Congress
Assessment of clinical peculiarities of violations of vertical vision in patients with Parkinson’s disease
M. Salokhiddinov, D. Akramova (Tashkent city, Uzbekistan)
Objective: To study vertical oculomotor reflexes and the state of the functional system "eyelid" in patients with PD. Background: Parkinson's disease (PD) is a common…
2018 International Congress
Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report
B. Lisewska, P. Lisewski, P. Szarwas, N. Piekuś-Słomka, D. Rość (Bydgoszcz, Poland)
Objective: We conducted a pilot study to determine the association between the neutrophil to lymphocyte ratio (NLR), he lymphocyte to monocyte ratio (LMR), the levels…
2018 International Congress
Alpha-synuclein oligomer and rotenone treatments injury the dopaminergic neuron via inhibiting the expression of gene SEMA6D
X. Yingyu (Guangzhou, China)
Objective: To investigate the expression of Semaphorin6D (SEMA6D) and its interaction with Plexin-A1 in cellular Parkinson's disease(PD) models induced by α-synuclein and rotenone. Background: In…
2018 International Congress
Measuring salivary cortisol levels in persons with Parkinson’s disease (PD)
A. Hiller, B. Lobb, J. Proulx, J. Quinn (Portland, OR, USA)
Objective: To better characterize the relationship between salivary cortisol and psychological stress in persons with Parkinson’s disease (PD). Background: Psychological stress is known to exacerbate…
2018 International Congress
Neuropsychiatric disorders in observed patients with Parkinson’s disease
S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)
Objective: Parkinson's disease (PD), - chronic progressive disease of the brain from the degeneration of the nigrostriatal neurons in the basal ganglia and impaired function.…
2018 International Congress
The International Parkinson and Movement Disorder Society Non-Motor Scale (MDS-NMS) for Parkinson’s Disease: Preliminary results from an international validation
K. Ray Chaudhuri, D. Weintraub, A. Rizos, A. Schrag, P. Martinez-Martin (London, United Kingdom)
Objective: To provide an update on the ongoing international validation programme of an expanded, refined and improved scale for the assessment of non-motor symptoms (NMS)…
2018 International Congress
Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study
J. Cedarbaum, K. Evans, M. Yang, J. Xiao (Cambridge, MA, USA)
Objective: In clinical trials for new PD therapies, it is common for patients to start to take approved symptomatic PD medications during the study. The…
2018 International Congress
Efficacy of zonisamide on motor symptoms in dementia with Lewy bodies: A post-hoc analysis of a phase 3 study
H. Maruyama, M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, K. Kosaka (Tokyo, Japan)
Objective: To characterize the efficacy of zonisamide in improving motor symptoms, we performed a post-hoc analysis using data from a phase 3 study that evaluated…